Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
PMID: 42341302 | N Engl J Med | Ruella M et al.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 10 | First 10-year follow-up data for any CAR-T product; definitively answers the "is this curative?" question |
| Clinical Relevance | 10 | Directly confirms cure potential; plateau in relapse curve after 5.4 yrs; also flags second malignancy risk |
| Population Reach | 7 | DLBCL/FL are common aggressive lymphomas; CAR-T currently limited to relapsed/refractory settings but expanding |
| Implementation Speed | 7 | Therapy already approved/available; data informs current practice immediately (surveillance, expectations) |
| Evidence Strength | 9 | Prospective long-term cohort; small n=38 is a limitation but expected at 10 yrs; NEJM peer review |
Key quantitative result: 10-yr LFS 32% (DLBCL), 47% (FL); 0 relapses beyond 5.4 years; 21% second primary cancer incidence. External validation: Single-institution long-term follow-up of original trial cohort; no independent replication yet but consistent with prior 5-yr reports. Main limitation: Small sample (n=38 evaluable); single institution; patient selection from early trial era may not reflect current practice. Equity implications: CAR-T access remains highly inequitable globally — patients with insurance, proximity to academic centers, and adequate performance status benefit most. Durable cure data may accelerate access advocacy but structural barriers persist. Evidence Maturity: ✅ Potentially Practice-Changing
Article 2 — Disparate privacy risks from medical AI
PMID: 42343130 | Nature | Knolle MA et al.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First patient-level privacy audit of medical AI; demonstrates near-perfect MIA success even when aggregate metrics look safe |
| Clinical Relevance | 7 | Does not directly change treatment; but fundamentally impacts AI deployment policy and patient safety |
| Population Reach | 10 | Every patient whose data trains a medical AI model is potentially affected — hundreds of millions globally |
| Implementation Speed | 6 | Regulatory/policy change is slow; technical mitigations (differential privacy) exist but deployment takes time |
| Evidence Strength | 8 | Nature publication; rigorous quantitative audit methodology; multiple demographic strata tested |
Key quantitative result: Near-perfect MIA success at patient level; disproportionate risk for underrepresented groups across race, sex, insurance status, disease status, imaging protocol. External validation: Methodologically novel; no direct replication yet but builds on established MIA literature. Main limitation: Generalizability across all medical AI architectures/modalities not fully established; specific model types and datasets used may not represent all deployed systems. Equity implications: Underrepresented groups (racial minorities, atypical disease presentations, lower socioeconomic status) face greater privacy exposure — a compounding injustice on top of existing representation gaps in AI training data. Evidence Maturity: ✅ Validated (methodologically); Exploratory for regulatory/mitigation implications
Article 3 — Automated reanalysis of genomic data for rare disease diagnostics at scale
PMID: 42343115 | Nat Med | Welland MJ et al.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Open-source automated pipeline with dynamic evidence integration; addresses the reanalysis bottleneck at scale |
| Clinical Relevance | 9 | 5.1% new diagnostic yield in previously undiagnosed patients = real diagnoses for real families; open-source enables immediate adoption |
| Population Reach | 8 | Rare diseases collectively affect ~300M people globally; diagnostic odyssey is a major unmet need |
| Implementation Speed | 8 | Open-source tool; already validated in 4,735 cases; can be integrated into existing genomic pipelines relatively quickly |
| Evidence Strength | 8 | Large prospective-adjacent validation cohort; Nature Medicine; multi-institutional |
Key quantitative result: 241 new diagnoses in 4,735 cases (5.1%); 32% from new gene-disease relationships; 90% sensitivity for known diagnoses in trio analysis. External validation: Large multi-center validation cohort provides strong internal validation; independent replication pending. Main limitation: Performance likely varies with sequencing depth, cohort ancestry, and local gene-disease database currency; implementation requires bioinformatics infrastructure. Equity implications: Rare disease diagnostic odyssey disproportionately burdens underserved communities with less access to genomic specialists. Open-source tool could democratize access — but only if sequencing infrastructure exists. Global South faces significant barriers. Evidence Maturity: ✅ Potentially Practice-Changing (for genomic diagnostic programs)
Article 4 — Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance
PMID: 42342704 | Nat Commun | Wright SJ et al.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Largest multimodal blood-based ICB biomarker study; mechanistic link between circulating proteins and tumor immune microenvironment |
| Clinical Relevance | 7 | Biomarker discovery stage; not yet actionable but directly informs patient stratification and trial design |
| Population Reach | 7 | Melanoma focus, but ICB resistance is a universal oncology problem affecting all solid tumors |
| Implementation Speed | 4 | Requires prospective clinical validation before clinical use; proteomics platforms not universally available |
| Evidence Strength | 7 | n=250 with multi-omic validation on 92 matched tumors; observational; discovery cohort needs independent validation |
Key quantitative result: >2,900 plasma proteins profiled; suppressive myeloid-linked proteins in non-responders; epithelial proteins in responders linked to immune-related toxicity. External validation: Internally validated with matched tumor RNA; no external replication cohort reported. Main limitation: Melanoma-only cohort; observational design; proteomic platforms (SomaScan/Olink) not universally standardized; causal direction unclear. Equity implications: Melanoma disproportionately affects white patients; findings may not generalize to populations with higher burden of other ICB-treated cancers (e.g., gastric, cervical). Evidence Maturity: 🔬 Exploratory
Article 5 — Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance
PMID: 42342869 | Nat Metab | Sandsdal RM et al.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Pre-specified secondary analysis; confirms exercise superiority over GLP-1RA alone for vascular endpoints — underappreciated finding |
| Clinical Relevance | 9 | Direct implication for how GLP-1RA prescribers counsel patients; exercise cannot be replaced by liraglutide for vascular benefit |
| Population Reach | 9 | Obesity and cardiovascular disease affect billions; GLP-1RA use is exploding globally |
| Implementation Speed | 9 | No new intervention needed; informs counseling immediately; applicable to primary care today |
| Evidence Strength | 8 | Pre-specified secondary RCT analysis; n=130; 52 weeks; Nature Metabolism; objective vascular endpoints (carotid IMT) |
Key quantitative result: Exercise (±liraglutide) reduces carotid IMT and IL-6/IFN-γ; liraglutide alone shows no significant vascular improvement; combination improves sICAM-1, sVCAM-1, tPA additionally. External validation: Pre-specified secondary analysis of S-LiTE RCT — methodologically strong; primary trial already published. Main limitation: Liraglutide is an older GLP-1RA (not semaglutide/tirzepatide); secondary analysis with reduced statistical power; n=130 limits subgroup analyses. Equity implications: GLP-1RAs are already inaccessible to many lower-income patients; exercise interventions face socioeconomic barriers (time, safety, access to facilities). Findings could widen health gaps if exercise benefit is acknowledged but not supported structurally. Evidence Maturity: ✅ Validated (within RCT framework); Potentially Practice-Changing for GLP-1RA counseling
Article 6 — TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens
PMID: 42342658 | Signal Transduct Target Ther | Ding Z et al.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First VHH-VHH bispecific targeting pMHC-I presented intracellular antigens — overcomes major limitation of current BiTEs |
| Clinical Relevance | 3 | Preclinical only; CDX/PDX models; human translation requires significant further development |
| Population Reach | 7 | Intracellular antigens (WT1, GPC3) are broadly expressed across hematologic and solid tumors |
| Implementation Speed | 2 | Early preclinical; IND-enabling studies, Phase I trials years away |
| Evidence Strength | 5 | Strong preclinical design (CDX + PDX); non-human cap applies; no toxicology or human data |
Key quantitative result: Significant tumor suppression and prolonged survival in CDX and PDX xenograft models; no treatment-related adverse effects. External validation: Proof-of-concept; no independent replication. Main limitation: Non-human models only; xenograft immune systems differ substantially from intact human immune systems; HLA-A2 restriction limits applicability to ~45% of patients. Equity implications: HLA-A2 restriction would exclude a larger proportion of East Asian, African, and Indigenous populations relative to European-ancestry populations. Evidence Maturity: 🔬 Exploratory
Article 7 — Phase II FT14 conditioning regimen in allogeneic HSCT for AML
PMID: 42342968 | Bone Marrow Transplant | Avenoso D et al.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Treosulfan+fludarabine combinations are known; this confirms myeloablative dose safety with prospective data |
| Clinical Relevance | 8 | Directly actionable for transplant teams; near-zero NRM is a compelling safety profile |
| Population Reach | 5 | AML in CR1, age 40-65 — defined but not small patient population |
| Implementation Speed | 7 | Phase II; treosulfan already available in Europe; could inform practice now pending Phase III |
| Evidence Strength | 7 | Multicenter prospective Phase II; n=82; short median follow-up (19.7 months) is the key caveat |
Key quantitative result: 1-yr LFS 81.7%; relapse incidence 14.9%; near-zero NRM; no graft failures. External validation: Multicenter but no randomized comparator arm; comparison to historical busulfan data is inferential. Main limitation: No randomized comparator; 19.7-month median follow-up insufficient for definitive LFS/OS conclusions; treosulfan availability varies by region. Equity implications: Middle-aged AML patients (40-65) who are ineligible for standard myeloablative regimens due to comorbidity may benefit; access limited by transplant center availability. Evidence Maturity: ✅ Validated (Phase II level); Phase III needed for practice change
Article 8 — LUNA25 Challenge: AI vs Radiologists for Lung Nodule Malignancy Risk
PMID: 42340186 | Radiol Artif Intell | Peeters D et al.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Relevance | 8 | Large-scale international benchmark; rigorous head-to-head comparison with 65 radiologists |
| Clinical Relevance | 8 | 12% more malignant nodules correctly classified at matched specificity; 20% fewer false positives — clinically meaningful |
| Population Reach | 9 | Lung cancer is the #1 cancer killer worldwide; screening CT increasingly deployed globally |
| Implementation Speed | 6 | AI systems exist; FDA/CE clearance pathways, workflow integration, and liability frameworks remain hurdles |
| Evidence Strength | 7 | Well-designed challenge study; external test set; however challenge-format selection and dataset curation introduce potential bias |
Key quantitative result: AI AUC 0.78 vs radiologist mean 0.70 (P=0.001); 12% more malignancies detected; 20% fewer false positives. External validation: Independent external test set; multi-reader (65 radiologists); international consortium. Main limitation: Challenge datasets may not reflect real-world nodule prevalence or clinical heterogeneity; radiologists read without clinical context; prospective clinical trial needed. Equity implications: AI screening tools could extend expert-level radiology to under-resourced settings — but require CT infrastructure, validated software, and regulatory clearance that many LMICs lack. Evidence Maturity: ✅ Validated (benchmark level); Exploratory for clinical deployment
Article 9 — Apotransferrin + induction chemotherapy in AML mouse models
PMID: 42341081 | Sci Transl Med | Lopes M et al.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Novel dual-action mechanism: iron redistribution simultaneously reduces AML burden and improves infection survival |
| Clinical Relevance | 3 | Mouse models only; non-human cap applies strictly |
| Population Reach | 6 | AML induction is a high-mortality event; infection is a leading cause of early death |
| Implementation Speed | 2 | Preclinical stage; clinical-grade apoTF production and trial design needed |
| Evidence Strength | 5 | Rigorous murine mechanistic study; multiple independent model systems; Science Translational Medicine curation; non-human cap |
Key quantitative result: ApoTF + chemotherapy reduces AML cells and improves survival (immune-dependent); apoTF increases E. coli sepsis survival; mechanism via decreased CCL2 and IL-6. External validation: Multiple murine models used (mechanistic strength); no human data. Main limitation: Mouse AML models poorly replicate human disease heterogeneity; apoTF safety/pharmacokinetics in humans unknown; immune-dependent effect may not translate. Equity implications: If translated, apoTF could benefit AML patients globally given its mechanism targets a universal complication (infection during induction) — potentially high equity impact. Evidence Maturity: 🔬 Exploratory
Article 10 — Meta-analysis of ctDNA vs PET response in Large B-Cell Lymphoma
PMID: 42341324 | Blood Adv | Gordon MJ et al.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Quantifies ctDNA superiority over PET for MRD assessment with HR data; 14× vs 5× prognostic effect |
| Clinical Relevance | 8 | Directly supports response-adapted clinical trials and MRD-guided de-escalation strategies |
| Population Reach | 6 | LBCL is the most common aggressive lymphoma but meta-analysis is only 367 patients |
| Implementation Speed | 5 | ctDNA platforms (phased-variant) not universally available; require standardization and validation |
| Evidence Strength | 6 | Meta-analysis of 3 studies, n=367; small pool; heterogeneity of assays across studies |
Key quantitative result: Undetectable MRD HR 14.02 vs detectable; PET CMR HR 5.09; 2-yr PFS 95.7% (MRD undetectable + CMR). External validation: Meta-analytic design provides pooled evidence; only 3 studies limits robustness. Main limitation: Small meta-analytic pool (3 studies, 367 patients); phased-variant ctDNA platform-specific (not generalizable to all ctDNA assays); PFS not OS. Equity implications: ctDNA testing currently expensive and limited to well-resourced centers; superior prognostic tool may not reach patients in LMICs or community settings. Evidence Maturity: ✅ Validated (prognostic tool); Exploratory for treatment adaptation
Article 11 — Fludarabine vs Bendamustine Lymphodepletion for CAR-T in LBCL
PMID: 42341926 | Transplant Cell Ther | Ahmed N et al.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Addresses known clinical equipoise; largest real-world dataset to date |
| Clinical Relevance | 9 | Directly actionable: allows individualized LD choice based on efficacy vs toxicity trade-off |
| Population Reach | 6 | LBCL CAR-T recipients — growing population but still relatively specialized |
| Implementation Speed | 9 | Real-world data; immediately applicable to clinical decision-making at CAR-T centers |
| Evidence Strength | 7 | n=5,256 CIBMTR real-world registry; large sample; retrospective/observational limitations apply |
Key quantitative result: Fludarabine: superior ORR (HR 0.773, P=.0013), better PFS; Bendamustine: lower CRS (OR 0.445), ICANS (OR 0.432), TRM; OS similar at 1-2 years. External validation: CIBMTR registry provides broad multi-center coverage; retrospective confounding possible. Main limitation: Retrospective observational design; selection bias in LD regimen choice; product mix (axi-cel, tisa-cel, liso-cel) heterogeneity. Equity implications: Toxicity-efficacy trade-off is especially relevant for older, frailer, or socioeconomically disadvantaged patients who may tolerate CRS/ICANS less well. Evidence Maturity: ✅ Validated (real-world evidence level)
Article 12 — Persistent infection risk after CD19 CAR-T: Australian cohort
PMID: 42341925 | Clin Microbiol Infect | Australian CAR-T infection cohort
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Pathogen-specific long-term infection characterization; complements 10-yr NEJM data |
| Clinical Relevance | 8 | Directly informs prophylaxis protocols and survivorship monitoring programs |
| Population Reach | 5 | CD19 CAR-T survivors — growing but still specialized population |
| Implementation Speed | 8 | Clinical guidance can be updated based on findings immediately |
| Evidence Strength | 6 | Multi-center cohort; Australia-specific; limited metadata provided in triage record |
Note: No DOI available; abstract-level metadata only — scores are conservative. Main limitation: Regional cohort (Australia); limited detail in available triage metadata; pathogen-specific data not fully described. Equity implications: Long-term infection management requires ongoing specialist access — underserved CAR-T survivors may be disproportionately affected. Evidence Maturity: ✅ Validated (observational)
Article 13 — FUBL-3/FUBP1 mediates mitochondrial stress-induced chromatin remodeling and longevity
PMID: 42341138 | Sci Adv | Zhang Q et al.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | New conserved mitochondria-to-nucleus signaling axis; FUBP1 human ortholog extends longevity mechanism |
| Clinical Relevance | 2 | C. elegans model; no human data; non-human cap applies |
| Population Reach | 8 | Aging biology is universal; but translation timeline is very long |
| Implementation Speed | 1 | Basic science discovery; therapeutic development is a decade or more away |
| Evidence Strength | 6 | Forward genetic screen + mechanistic follow-up in C. elegans; human FUBP1 conservation data is supportive but limited |
Key quantitative result: FUBL-3 overexpression sufficient to extend lifespan; human FUBP1 rescues mutant phenotypes and binds proteostasis/mitochondrial gene promoters. Main limitation: Worm-to-human translation is highly uncertain; FUBP1 is also a known oncogene — potential dual-edged biology. Equity implications: Longevity interventions historically skew toward wealthy populations; basic science stage too early to assess. Evidence Maturity: 🔬 Exploratory
Articles 14–25 — Abbreviated Phase 2 Assessments
| # | PMID | Title (short) | Novelty | Clin Rel | Pop Reach | Impl Speed | Evid Str | Maturity |
|---|---|---|---|---|---|---|---|---|
| 14 | 42341444 | CD244 in AML CD8+ T cells | 6 | 5 | 4 | 3 | 5 | Exploratory |
| 15 | 42341445 | FLAMSA vs FLAG-IDA salvage AML | 4 | 6 | 4 | 6 | 5 | Validated (retrospective) |
| 16 | 42341321 | Late cytopenia after CD19 CAR-T | 5 | 7 | 5 | 7 | 6 | Validated |
| 17 | 42339787 | Leukocyte data predict CAP mortality | 6 | 7 | 7 | 7 | 6 | Validated |
| 18 | 42340652 | ctDNA RAS tracking in mCRC | 5 | 6 | 6 | 5 | 5 | Exploratory |
| 19 | 42341616 | Desmoid tumor molecular profiling | 7 | 5 | 3 | 3 | 5 | Exploratory |
| 20 | 42341369 | HER2 targeting in urothelial Ca | 4 | 6 | 6 | 5 | 5 | Validated (review) |
| 21 | 42341515 | Peroxisomal disorders in Sweden | 4 | 5 | 3 | 5 | 7 | Validated (epi) |
| 22 | 42341949 | Genomics of prostate Ca on surveillance | 6 | 6 | 6 | 4 | 6 | Exploratory |
| 23 | 42343035 | Gut microbiota and aging (review) | 4 | 4 | 7 | 5 | 4 | Exploratory |
| 24 | 42337454 | ML model: chikungunya vs dengue | 5 | 6 | 6 | 6 | 5 | Exploratory |
| 25 | 42343091 | BV maintenance in Hodgkin by pre-transplant status | 5 | 7 | 4 | 7 | 5 | Validated (real-world) |
PHASE 3 — Ranking
Conflict Check
No direct conflicts between articles. Articles 1, 11, 12, and 16 are complementary on the CAR-T topic (long-term outcomes, LD choice, infection risk, late cytopenia) — they collectively build a consistent picture of mature CAR-T survivorship data without contradiction.
Articles 5 (exercise + liraglutide) does not conflict with broader GLP-1RA cardiovascular literature (LEADER trial showed cardiovascular benefit for liraglutide) but narrows it: liraglutide's cardiovascular outcomes trial benefit may not include vascular structural changes achievable through exercise.
Ranked Impact Table
Composite Score Formula: Impact = (Clinical Relevance × 0.30) + (Population Reach × 0.25) + (Scientific Novelty × 0.20) + (Implementation Speed × 0.15) + (Evidence Strength × 0.10)
| Rank | PMID | Short Title | Flag | Impact Score | Clin Rel | Pop Reach | Novelty | Impl Speed | Evid Str | OpenClaw Score | Study Design |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 🥇 1 | 42341302 | 10-Year CAR-T Outcomes DLBCL/FL | 🟠 | 8.90 | 10 | 7 | 10 | 7 | 9 | 10 | Prospective long-term follow-up |
| 🥈 2 | 42342869 | Exercise vs Liraglutide Vascular RCT | 🟢 | 8.75 | 9 | 9 | 7 | 9 | 8 | 8 | Pre-specified RCT secondary analysis |
| 🥉 3 | 42343115 | Talos Automated Rare Disease Reanalysis | 🟢🟡 | 8.55 | 9 | 8 | 8 | 8 | 8 | 9 | Large-scale validation cohort |
| 4 | 42340186 | LUNA25 AI vs Radiologists Lung Nodule | 🔴🟢 | 8.33 | 8 | 9 | 8 | 6 | 7 | 8 | International benchmark challenge |
| 5 | 42343130 | Disparate Privacy Risks Medical AI | 🟡 | 8.05 | 7 | 10 | 9 | 6 | 8 | 9 | Quantitative privacy audit |
| 6 | 42341926 | Fludarabine vs Bendamustine CAR-T LD | 🟢 | 7.70 | 9 | 6 | 6 | 9 | 7 | 7 | Retrospective real-world registry (CIBMTR, n=5,256) |
| 7 | 42341324 | ctDNA vs PET MRD Meta-analysis LBCL | 🔴 | 7.18 | 8 | 6 | 7 | 5 | 6 | 7 | Meta-analysis (3 studies, n=367) |
| 8 | 42342968 | FT14 Conditioning AML Phase II | 🟠 | 7.15 | 8 | 5 | 6 | 7 | 7 | 8 | Multicenter prospective Phase II |
| 9 | 42342704 | Blood Proteomics ICB Resistance Melanoma | ⚪ | 6.85 | 7 | 7 | 8 | 4 | 7 | 8 | Observational multiomics cohort |
| 10 | 42341321 | Late Cytopenia After CD19 CAR-T | ⬜ | 6.70 | 7 | 5 | 5 | 7 | 6 | 6 | Multi-center consortium cohort |
| 11 | 42339787 | Leukocyte Data Predict CAP Mortality | 🟢 | 6.65 | 7 | 7 | 6 | 7 | 6 | 6 | Multicenter prospective |
| 12 | 42341925 | Long-term Infection Risk CD19 CAR-T | ⬜ | 6.55 | 8 | 5 | 6 | 8 | 6 | 7 | Multi-center cohort |
| 13 | 42341081 | ApoTF + Chemo in AML Mouse Models | ⚪ | 4.55 | 3 | 6 | 8 | 2 | 5 | 8 | Preclinical murine |
| 14 | 42343091 | BV Maintenance Hodgkin Post-Transplant | ⬜ | 5.85 | 7 | 4 | 5 | 7 | 5 | 5 | Real-world multicenter |
| 15 | 42341949 | Genomics Prostate Ca on Surveillance | ⚪ | 5.65 | 6 | 6 | 6 | 4 | 6 | 6 | Genomic cohort study |
| 16 | 42340652 | RAS ctDNA Dynamics mCRC Bevacizumab | ⚪ | 5.60 | 6 | 6 | 5 | 5 | 5 | 6 | Longitudinal observational |
| 17 | 42341445 | FLAMSA vs FLAG-IDA Salvage AML | ⬜ | 5.35 | 6 | 4 | 4 | 6 | 5 | 6 | Single-center retrospective |
| 18 | 42337454 | ML Model Chikungunya vs Dengue | 🟡 | 5.80 | 6 | 6 | 5 | 6 | 5 | 5 | ML validation study |
| 19 | 42342658 | TCR-mimic Bispecific Nanobody Engager | ⚪ | 4.65 | 3 | 7 | 9 | 2 | 5 | 8 | Preclinical CDX/PDX |
| 20 | 42341138 | FUBL-3/FUBP1 Longevity C. elegans | ⚪ | 4.30 | 2 | 8 | 8 | 1 | 6 | 7 | Basic science, C. elegans |
| 21 | 42341616 | Desmoid Tumor Molecular Profiling | ⚪ | 4.80 | 5 | 3 | 7 | 3 | 5 | 6 | Molecular profiling cohort |
| 22 | 42341444 | CD244 in AML Bone Marrow T Cells | ⚪ | 4.70 | 5 | 4 | 6 | 3 | 5 | 6 | Translational cohort study |
| 23 | 42341369 | HER2 Targeting Urothelial Carcinoma | ⬜ | 5.25 | 6 | 6 | 4 | 5 | 5 | 6 | Systematic review |
| 24 | 42341515 | Peroxisomal Disorders Sweden Incidence | 🟡 | 4.75 | 5 | 3 | 4 | 5 | 7 | 6 | National registry epidemiology |
| 25 | 42343035 | Gut Microbiota and Aging Review | ⬜ | 4.85 | 4 | 7 | 4 | 5 | 4 | 6 | Narrative/comprehensive review |
Rank Justifications for Top 8
#1 — Ten-Year CAR-T Outcomes | Impact 8.90 | 🟠 This is a landmark paper in the strictest sense of the word. It answers a question that has hung over the CAR-T field since its inception: is this actually curative? The answer — at least for a meaningful subset — is yes. A 10-year follow-up with a clear plateau in the relapse curve after 5.4 years, published in NEJM, shifts the conversation from "promising experimental therapy" to "established curative option." The simultaneous signal of a 21% second primary cancer rate adds critical long-term safety context that will reshape survivorship monitoring. Despite a small sample (n=38), this is essentially the entire eligible cohort surviving to 10 years, making it the best evidence that can realistically exist at this time horizon. Why it matters: Thousands of patients with relapsed/refractory DLBCL and FL are now in or approaching the window where this data applies — and their oncologists can counsel them with genuine evidence of cure rather than hope.
#2 — Exercise vs Liraglutide Vascular RCT | Impact 8.75 | 🟢 In the era of GLP-1RA prescription surges, this RCT delivers a pointed message: liraglutide alone does not improve vascular structure or systemic inflammation during weight maintenance — exercise does. The pre-specified design in Nature Metabolism gives this finding methodological credibility that a post-hoc analysis could not. The implications land squarely in primary care, where GLP-1RA prescriptions are often written without exercise counseling. Carotid IMT reduction is not a soft endpoint — it's a validated surrogate for atherosclerotic burden. Why it matters: With hundreds of millions on or considering GLP-1RAs, this finding argues urgently that exercise co-prescription is not optional if vascular risk reduction is a clinical goal.
#3 — Talos Automated Rare Disease Genomic Reanalysis | Impact 8.55 | 🟢🟡 Five percent sounds modest until you remember these are patients who had already exhausted conventional diagnostic pathways — families who had often been told there was no answer. Talos delivers answers to 1 in 20 of them using an automated, open-source pipeline that runs monthly on updated gene-disease evidence. The 90% sensitivity in trio analysis and 241 real diagnoses in 4,735 patients make this immediately deployable for any genomic diagnostic program. Why it matters: For rare disease families, a diagnosis ends the diagnostic odyssey, enables treatment decisions, guides reproductive counseling, and connects them to a disease community. This tool scales that possibility.
#4 — LUNA25 AI Lung Nodule Benchmark | Impact 8.33 | 🔴🟢 An AUC difference of 0.78 vs 0.70 translates to 12% more cancers caught at the same false-positive rate — or 20% fewer unnecessary follow-up procedures at the same detection rate. In lung cancer screening populations where millions of indeterminate nodules are generated annually, this performance gap has real mortality implications. The 65-radiologist comparison and external test set design make this among the most rigorous head-to-head AI-vs-human benchmarks published. Why it matters: Lung cancer kills ~1.8 million people per year globally; catching more malignant nodules earlier, with fewer false alarms, is directly life-saving.
#5 — Disparate Privacy Risks in Medical AI | Impact 8.05 | 🟡 This Nature study doesn't just show that medical AI can be attacked — it shows that the patients who are already underrepresented in training data face the greatest privacy exposure when those models are deployed. Aggregate privacy metrics are insufficient. Patient-level membership inference attacks succeed even when model-level statistics appear safe, and the disparity falls along familiar lines: race, insurance status, sex. Why it matters: Every hospital deploying a medical AI model trained on patient data is potentially exposing individual patients to re-identification — and the burden falls disproportionately on the most vulnerable.
#6 — Fludarabine vs Bendamustine CAR-T LD, CIBMTR | Impact 7.70 | 🟢 With n=5,256 patients across three commercial CAR-T products, this is the definitive real-world answer to a debate every CAR-T program has been having informally. Fludarabine wins on response; bendamustine wins on toxicity; OS converges at 1-2 years. This allows genuinely individualized decision-making based on patient risk profile. Why it matters: The choice of lymphodepletion chemotherapy is a modifiable variable at every CAR-T center — this data gives clinicians a robust evidence base to optimize it patient by patient.
#7 — ctDNA vs PET MRD Meta-analysis LBCL | Impact 7.18 | 🔴 The HR of 14 for undetectable ctDNA vs HR of 5 for PET negativity is a striking quantitative argument for ctDNA as the superior MRD tool in LBCL. The 95.7% 2-year PFS for patients achieving both endpoints provides a potential benchmark for response-adapted trial design. The small meta-analytic pool (3 studies, 367 patients) keeps confidence intervals wide, but the consistency across studies is notable. Why it matters: Better MRD tools mean better-designed clinical trials and, eventually, better-targeted de-escalation or intensification strategies for lymphoma patients.
#8 — FT14 Conditioning AML Phase II | Impact 7.15 | 🟠 An 81.7% 1-year LFS with near-zero NRM in a prospective multicenter setting addresses a genuine evidence gap for middle-aged AML transplant patients. The absence of a randomized comparator is a meaningful caveat, but for a Phase II signal-finding study, these are compelling numbers. Why it matters: Transplant-related mortality has historically been the barrier to curative-intent allo-HSCT in this age group — a conditioning regimen with near-zero NRM could expand access to potentially curative transplantation.